Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure-Reference-Cited by-同舟云学术

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Published:2021-09 Issue:13 Volume:78 Page:1337-1348
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Böhm Michael,Anker Stefan D.,Butler Javed,Filippatos Gerasimos,Ferreira João Pedro,Pocock Stuart J.,Mahfoud Felix,Brueckmann Martina,Jamal Waheed,Ofstad Anne Pernille,Schüler Elke,Ponikowski Piotr,Wanner Christoph,Zannad Faiez,Packer Milton

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

2. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus;Kato;Circulation,2019

3. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial;Fitchett;Circulation,2019

4. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

5. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure;Packer;N Engl J Med,2020

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haemodynamic Effects of Sodium–Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients;Cardiac Failure Review;2024-09-11

2. Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation;ACS Pharmacology & Translational Science;2024-08-01

3. “The Bigger the Ship, the Harder It Is to Turn: Continued Clinical Inertia With SGLT2i Utilization in Heart Failure”;Journal of Cardiac Failure;2024-06

4. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC;European Journal of Heart Failure;2024-05-22

5. Empagliflozin in the treatment of heart failure;Future Cardiology;2024-04-25